Serogroup B meningococcal vaccines-an unfinished story

The Lancet Infectious Diseases
Manish Sadarangani, Andrew J Pollard

Abstract

Most invasive meningococcal disease in developed countries is caused by Neisseria meningitidis with a serogroup B capsule. However, despite availability of vaccines for other serogroups since the 1960s, no serogroup B vaccine exists. In this Review we look at the development of serogroup B vaccines over the past 40 years. Outer membrane vesicle vaccines have been successfully used to control geographically isolated epidemics, but most have not been highly immunogenic in young children or provided broad cross-protection from infections with other strains. Vaccines based on subcapsular antigens have recently produced promising results in early clinical trials, and the disease burden might be substantially reduced over the next few years.

References

Jun 1, 1978·The Journal of Infectious Diseases·W D ZollingerM S Artenstein
May 1, 1979·The Journal of Clinical Investigation·W D ZollingerS Berman
Nov 1, 1972·The Journal of Infectious Diseases·F A WyleJ P Lowenthal
Nov 1, 1973·The Journal of Experimental Medicine·I W Devoe, J E Gilchrist
Jun 1, 1969·The Journal of Experimental Medicine·I GoldschneiderM S Artenstein
Jun 1, 1969·The Journal of Experimental Medicine·I GoldschneiderM S Artenstein
Apr 18, 1998·Proceedings of the National Academy of Sciences of the United States of America·M C MaidenB G Spratt
Jul 23, 1998·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·D A Caugant
Aug 13, 1999·Memórias do Instituto Oswaldo Cruz·A P RodriguezR Martinez
Sep 23, 2000·Journal of Biotechnology·D MartinR W Ellis
Sep 8, 2001·The New England Journal of Medicine·I LaurensonC Thompson
Mar 12, 2002·Journal of Paediatrics and Child Health·M G BakerD Lennon
Mar 19, 2003·The Journal of Experimental Medicine·Vega MasignaniMariagrazia Pizza
Mar 25, 2004·Infection and Immunity·Leah D FletcherGary W Zlotnick
Jun 15, 2006·Journal of Medical Microbiology·UNKNOWN Meningococcal Reference UnitEdward B Kaczmarski
Oct 7, 2006·Vaccine·Germie P J M van den DobbelsteenLoek van Alphen
Jul 7, 2007·American Journal of Epidemiology·Colleen KellyJane O'Hallahan
Feb 27, 2008·Journal of Leukocyte Biology·Susanna FranzosoEmanuele Papini

❮ Previous
Next ❯

Citations

Sep 17, 2010·The Pediatric Infectious Disease Journal·Matthew D SnapeAndrew J Pollard
Jul 29, 2011·Science Translational Medicine·Andrew J Pollard, Adrian V S Hill
Dec 15, 2010·Seminars in Immunopathology·Can M UnalKristian Riesbeck
Jun 20, 2015·Critical Reviews in Microbiology·Yih-Ling TzengDavid S Stephens
Feb 24, 2015·Expert Review of Vaccines·Nathan James Brendish, Robert Charles Read
Dec 9, 2014·Expert Opinion on Biological Therapy·Christine S RollierAndrew J Pollard
Aug 29, 2012·Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie·M-A Dommergues
Jul 2, 2015·Journal of Korean Medical Science·Sun-Myoung LeeJin-Soo Lee
Aug 27, 2015·Human Vaccines & Immunotherapeutics·Cosmina HogeaAndrew Vyse
Sep 18, 2015·Journal of Immunology Research·João Henrique CamposAna Claudia Torrecilhas
Sep 12, 2015·Journal of Immunology Research·Paolo DurandoAntoni Torres
Apr 17, 2013·Vaccine·Julie A BettingerUNKNOWN members of the Canadian Immunization Monitoring Program, Active (IMPACT)
Jan 8, 2014·Expert Review of Vaccines·Susanna Esposito, Nicola Principi
Aug 1, 2015·BMC Infectious Diseases·Keith D Poore, Chris T Bauch
Apr 29, 2015·The Journal of Infection·Simon B Drysdale, Andrew J Pollard
May 25, 2012·Vaccine·Brian GreenwoodMiguel O'Ryan
May 25, 2012·Vaccine·Matthew J BottomleyKeith P Klugman
Aug 8, 2012·Vaccine·Sílvia SantosRocilda Perazzini Furtado Schenkman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Antibodies: Complement Activation

The complement system can be activated by antigen-associated antibody. In the classical pathway of complement activation, C1q, C4b, and C3b are all able to bind to the Fc portion of IgG or IgM. Find the latest research on antibodies and complement activation here.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.